BioLine RX BLRX 深 滬
交易中 01-28 11:14:15 美东时间
3.00
-0.050
-1.64%
華盛通- 最 高3.09
- 今 開3.09
- 成交量 1388股
- 最 低 3.00
- 昨 收 3.05
- 總市值 1305.42万
- 52周最高 7.7699
- 市盈率 靜 --
- 換手率 0.03%
- 52周最低 2.3001
- 委 比 0.00%
- 總股本 435.14万
- 歷史最高 4122.00
- 量 比 0.34
- 振 幅 2.95%
- 歷史最低 2.70
- 每 手 1
- 風險率 0.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioLine Rx Q3 EPADS $(0.22) Beats $(1.20) Estimate, Sales $427.000K Miss $990.000K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(1.20) by 81.67 percent. This is a 214.29 percent decrease over losses of $(0.07) per share from the
2025-11-25 06:36
Earnings Scheduled For November 24, 2025
Companies Reporting Before The Bell • Lotus Technology (NASDAQ:LOT) is likely t...
2025-11-24 19:11
BioLine Rx's Earnings: A Preview
BioLine Rx (NASDAQ:BLRX) is gearing up to announce its quarterly earnings on Mo...
2025-11-21 23:01
BioLineRx Secures USPTO Patent Allowance for Cancer Treatment with GLIX1
Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has provided an update. On November 17...
2025-11-17 20:27
BioLineRx And Hemispherian Establish JV To Develop GLIX1, Oral, Small Molecule Targeting DNA Damage Response In Glioblastoma And Other Cancers
- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only -- FDA IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 -- Glioblastoma market opportunity estimated to be in excess of $3.8 billion annually across the US and EU5 by 2030 -
2025-09-29 19:13
UPDATE: BioLine Rx Q2 EPADS $(1.00) Beats $(1.20) Estimate, Sales $304.000K Miss $924.000K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.20) by 16.67 percent. The company reported quarterly sales of $304.000 thousand which missed the
2025-08-14 22:12
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
2025-08-14 16:32
Examining the Future: BioLine Rx's Earnings Outlook
BioLine Rx (NASDAQ:BLRX) is preparing to release its quarterly earnings on Thur...
2025-08-14 00:02
Where BioLine Rx Stands With Analysts
In the latest quarter, 4 analysts provided ratings for BioLine Rx (NASDAQ:BLRX)...
2025-06-17 20:00
美股大行评级 | 潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
2025-06-02 13:32
